Te-An Lee

Te-An Lee

Auto-generated profile, based on publicly available information

Te-An Lee

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in EBioMedicine
Verified
Journal Article
Open access
HHHsiang-Chi Huang
Hsiang-Chi Huang
YLYun-Ju Lai
Yun-Ju Lai
CLChun-Che Liao
Chun-Che Liao
FWFeng-Yang Wang
Feng-Yang Wang
KHKe-Bin Huang
Ke-Bin Huang
CLChia-Wei Li
Chia-Wei Li
Despite clinical success with anti-spike vaccines, the effectiveness of neutralizing antibodies and vaccines has been compromised by rapidly spreading SARS-CoV-2 variants. Viruses can hijack the glycosylation machinery of host cells to shield themselves from the host's immune response and attenuate antibody efficiency. However, it remains unclear if targeting glycosylation on viral spike protein can impair infectivity of SARS-CoV-2 and its variants. We adopted flow cytometry, ELISA, and BioLayer interferometry approaches to assess binding of glycosylated or deglycosylated spike with ACE2. Viral entry was determined by luciferase, immunoblotting, and immunofluorescence assays. Genome-wide association study (GWAS) revealed a significant relationship between STT3A and COVID-19 severity. NF-κB/STT3A-regulated N-glycosylation was investigated by gene knockdown, chromatin immunoprecipitation, and promoter assay. We developed an antibody-drug conjugate (ADC) that couples non-neutralization anti-spike antibody with NGI-1 (4G10-ADC) to specifically target SARS-CoV-2-infected cells. The receptor binding domain and three distinct SARS-CoV-2 surface N-glycosylation sites among 57,311 spike proteins retrieved from the NCBI-Virus-database are highly evolutionarily conserved (99.67%) and are involved in ACE2 interaction. STT3A is a key glycosyltransferase catalyzing spike glycosylation and is positively correlated with COVID-19 severity. We found that inhibiting STT3A using N-linked glycosylation inhibitor-1 (NGI-1) impaired SARS-CoV-2 infectivity and that of its variants [Alpha (B.1.1.7) and Beta (B.1.351)]. Most importantly, 4G10-ADC enters SARS-CoV-2-infected cells and NGI-1 is subsequently released to deglycosylate spike protein, thereby reinforcing the neutralizing abilities of antibodies, vaccines, or convalescent sera and reducing SARS-CoV-2 variant infectivity. Our results indicate that targeting evolutionarily-conserved STT3A-mediated glycosylation via an ADC can exert profound impacts on SARS-CoV-2 variant infectivity. Thus, we have identified a novel deglycosylation method suitable for eradicating SARS-CoV-2 variant infection in vitro. A full list of funding bodies that contributed to this study can be found in the Acknowledgements section

17 January 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Ongoing clinical trial of phosphorylation-associated small molecule drugs and anti-PD-1/PD-L1 combination

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
The biological function of PD-1 on immune cells and cancer cells

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.